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Abstract
Background and Aim: The association of fecal calprotectin (FC) and endoscopic response
in inflammatory bowel disease patients during vedolizumab (VDZ) treatment is largely un-
known. The aim of this study is to assess the diagnostic value of FC to predict endoscopic
response.
Methods: Patients with active endoscopic disease at baseline were included. Endoscopies
and FC tests were performed at baseline and week 16. Patients with a confirmed endo-
scopic response at week 16 continued VDZ maintenance therapy, and endoscopy and FC
tests were performed at week 52. Endoscopic response was defined as endoscopic Mayo
score reduction of ≥ 1, SES-CD of ≥ 50%, or Rutgeerts’ score of ≥ 1. Correlations were
assessed using Spearman and receiver operating characteristic statistics.
Results: A total of 114 patients, 46 ulcerative colitis and 68 Crohn’s disease patients
(44 men, median age 40 years), were included after the start of VDZ; 85% was
anti-tumor necrosis factor alpha refractory. Endoscopic response was observed in 60
(53%) patients at week 16; the response sustained in 73% at week 52. FC decreased signif-
icantly from 819 at baseline to 154 μg/g at week 16. FC at weeks 16 and 52 were signifi-
cantly correlated to (sustained) endoscopic response (r = 0.62 / r = 0.67, P < 0.001).
FC< 200 μg/g indicates endoscopic response (area under the curve = 0.89, positive predic-
tive value = 94%), whereas FC > 450 μg/g indicates endoscopic non-response after induc-
tion (negative predictive value = 83%). An increase in FC level of > 400 μg/g after
induction indicates endoscopic loss of response (area under the curve = 0.97, negative pre-
dictive value = 96%).
Conclusion: This prospective study demonstrates a significant correlation between FC and
endoscopic response to VDZ. FC < 200 μg/g prognosticate endoscopic response, and
FC > 450 μg/g endoscopic non-response. An increase in FC of > 400 μg/g after induction
indicates endoscopic loss of response. This simple FC algorithm may guide clinical deci-
sions on the continuation and optimization of VDZ in inflammatory bowel disease patients.
Introduction
Vedolizumab (VDZ) is a gut-selective humanized monoclonal
anti-α4β7 integrin and an effective treatment option for ulcerative
colitis (UC) and Crohn’s disease (CD).1–3 Although VDZ has
yielded a manifest position in inflammatory bowel disease (IBD)
treatment after registration, an important drawback for clinical de-
cisions on the use of VDZ is the uncertainty on the objective effi-
cacy of VDZ as induction strategy. The evaluation of the effect of
VDZ induction therapy preferably combines objective response to
substantiate subjective improvement of symptoms, as endoscopic
remission is associated with improved prognosis.4–8 Clinical data
on the effect of VDZ induction therapy are available abundantly.
For instance, the registration trials (GEMINI) reported response
of 47% in UC and 31% in CD patients at week 6.9,10 In addition,
a meta-analysis of real-world studies showed clinical remission in
50% of anti-tumor necrosis factor (TNF)-naïve patients and 30%
of anti-TNF refractory patients at week 14.11 Prospective data on
objective parameters of response to VDZ with endoscopy and
biochemistry (fecal calprotectin [FC]) are gradually emerging.
Recently, important data on endoscopic and histological response
to VDZ have been reported.12–14 In these studies, endoscopic
response to VDZ was 25–40% at week 26 and approximately
50% at week 52 with histological response in 24% at week 26
and 34% at week 52.13 In current practice, clinical decisions on
therapy continuation or optimization strategies are often scheduled
after VDZ induction; therefore, more data on the objective
response after induction in real-world studies are required. In addi-
tion, non-invasive markers such as FC to substitute endoscopy are
preferred in these situations. In this prospective cohort study, we
assessed the diagnostic value of FC to predict endoscopic response
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after VDZ induction at week 16 and to develop a simple algorithm
for clinical practice. As secondary aim, the diagnostic value of FC
to predict a sustained (endoscopic) response to VDZ will be
assessed.
Methods
Study population. Adult patients with UC, IBD unclassified
(IBD-U), and CD who started VDZ between October 2014 and
January 2019 at the Erasmus University Medical Center (EMC)
with active disease at baseline endoscopy were included. Baseline
clinical and demographic characteristics (age, gender, smoking
status, disease characteristics, and treatment history) were
collected.
Vedolizumab therapy. VDZ induction therapy consisted of
four 300-mg infusions for UC patients and was scheduled at week
0 (baseline), week 2, week 6, and week 14. CD patients received
an additional VDZ infusion at week 10. For patients with an endo-
scopic response at week 16, VDZ maintenance infusions were
scheduled every 8 weeks. Dose escalation of VDZ therapy was ac-
cepted and was left to the discretion of the treating physician.
Endoscopic assessment. Colonoscopy and FC tests were
performed at baseline and week 16. Patients with a confirmed en-
doscopic response at week 16 continued VDZ maintenance ther-
apy. In these patients, colonoscopy and FC tests were repeated at
week 52. Endoscopic inflammation was determined using the
scores as depicted in Table S1. Endoscopic remission was defined
as an endoscopic Mayo score of 0, SES-CD of ≤ 2, and a
Rutgeerts’ score of i0 or i1. Endoscopic response was defined as
a decrease of 1 or more points in the endoscopic Mayo score,
≥ 50% decrease in SES-CD score, or a decrease of 1 or more
points in the Rutgeerts’ score. In patients with an ileostomy,
ileoanal pouch anastomosis, or ileorectal anastomosis, endoscopic
disease activity was classified as no, mild, moderate, or severe as
judged by the endoscopist. Remission was defined as “no endo-
scopic disease activity” and response as a decrease of ≥ 1 point
on the above mentioned 4-grade scale. Endoscopic inflammation
was further categorized as shown in Table S1.
Sustained effectiveness was defined as an endoscopic response
at week 16 that sustained at week 52. Endoscopic loss of response
(eLOR) was defined as an increase in Mayo endoscopic score of
≥ 1 point, SES-CD increase of ≥ 50%, or Rutgeerts’ score increase
of ≥ 1 point in patients with an initial endoscopic response
achieved at week 16 (induction).
Fecal calprotectin measurements. At baseline, weeks
16 and 52 FC was determined using a quantitative
enzyme-linked immunosorbent assay (ELISA) (Bühlmann Labo-
ratories AG, Schönenbuch, Switzerland) or with the QuantOn
Cal (QoC) (Preventis, Germany) FC home test.15 During follow-
up, patients were offered the same FC measurement technique.
Statistical analysis. Descriptive statistics were used for
baseline characteristics. Continuous data were presented as
mean ± standard deviation (SD) or median with interquartile range
Figure 1 Flowchart of patient inclusion. MRE,
magnetic resonance enterography.
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(25th to 75th) according to the distribution. Categorical data were
presented in percentages. IBD-U patients were included in the UC
group for analysis. Chi-square test or Wilcoxon rank sum test was
used to evaluate differences in categorical or continuous
not-normally distributed data, between UC and CD patients. The
principal endpoint of interest was endoscopic response at week
16. A multivariable logistic regression analysis was performed to
identify predictors of endoscopic response at week 16. Variables
with significance level of < 0.2 on univariate analysis and based
on literature were included in the multivariable model. Additional
analyses were performed to evaluate the endpoints of sustained en-
doscopic response at week 52 and endoscopic remission at week
16 and at week 52. The correlation between week 16 and week
52 FC and (sustained) endoscopic response, endoscopic remission,
and endoscopic disease activity was analyzed using a
non-parametric two-tailed Spearman’s rank correlation test. For
FC, a delta (FC at baseline  FC at week 16/FC at week
16  FC at week 52) and a % decrease were calculated. Sensitiv-
ity, specificity, positive predictive value (PPV), and negative pre-
dictive value (NPV) of FC were calculated on endoscopic
response, endoscopic remission, and endoscopic disease activity
(no/mild/moderate/severe) using receiver operating characteristic
(ROC) statistics. The optimal cut-off (highest clinical relevant
PPV/NPV) was determined using the ROC curve for FC and endo-
scopic outcome. A two-sided P-value of < 0.05, and an area under
the curve (AUC) of ≥ 0.80, was considered significant. A correla-
tion coefficient of > 0.6 was considered as strong correlation. All
statistical analyses were performed using IBM SPS Statistics ver-
sion 24.0 (IBM Corp. Released 2013, IBM Corp, Armonk, NY).
The study protocol was approved by the Medical Ethics Commit-
tee (METC) Rotterdam, The Netherlands, MEC-2018-1187.
Results
In total, 134 patients received VDZ during the study period, of
whom 20 patients were excluded due to various reasons (Fig. 1).
The study population comprised 114 patients (38 UC [33%], 8
IBD-U [7%], and 68 CD patients [60%]) with a median age of
40 years (Table 1). VDZ was initiated after a median disease dura-
tion of 14 years (8 - 20). In total, 104/114 patients (91%) were ex-
posed to one or more anti-TNF drugs prior to the start of VDZ, of
whom 88/104 (85%) were anti-TNF refractory, defined as clinical
primary failure or secondary loss of response and 16/104 (15%)
stopped anti-TNF due to side effects.
In 74/114 patients (65%), initiation of VDZ was combined with
corticosteroid induction therapy (prednisolone in 42/114 patients
[37%]; budesonide in 32/114 patients [28%]) and was completely
tapered at week 16 in 50/74 (68%) patients, without statistical dif-
ference between UC and CD patients. In total, 27/114 patients
(24%) were on concomitant immunomodulator (IM) therapy.
Endoscopic response. Endoscopic response was observed
in 60/114 (53%) patients at week 16 (28/46 UC and 32/68 CD,
P = 0.18). Endoscopic remission at week 16 was observed in
23/114 (20%) patients (10/46 UC and 13/68 CD, P = 0.81)
(Fig. S1). Twenty-one patients used corticosteroids at week 16,
of whom 15/21 (71%) were endoscopic non-responders
(P = 0.071). Patients on concomitant IM therapy at baseline
showed lower endoscopic response rates as compared with pa-
tients without concomitant IM therapy (9/27, 33% vs 51/87,
59%; P = 0.03), whereas no significant difference was observed
for endoscopic remission (2/27, 7% vs 21/87, 24%; P = 0.10).
Only 2/27 (7%) patients on concomitant IM therapy received dose
optimization of thiopurine treatment before week 16; both patients
were endoscopic non-responders. No patients started new (con-
comitant) immunomodulatory therapy during 16 weeks of VDZ
treatment.
Table 1 Baseline patient characteristics
N = 114
Male, n (%) 44 (38.6)
Median age (years) (25th to 75th) 39.8 (31.0–49.7)
Smoking, n (%)
Yes 22 (21.2)
No 82 (78.8)
Median disease duration (years) (25th to 75th) 13.8 (7.8–20.1)
Diagnosis, n (%)
UC 38 (33.3)
IBD-U 8 (7)
CD 68 (59.6)
+ Perianal disease 19 (27.9)
CD disease location, n (%)
L1 ileal 6 (8.8)
L2 colonic 13 (19.1)
L3 ileocolonic 49 (72.1)
+ L4 upper GI disease 6 (8.8)
CD disease behavior, n (%)
B1 29 (42.6)
B2 30 (44.1)
B3 9 (13.2)
UC disease location, n (%)
E2 17 (37.0)
E3 29 (63.0)
Previous IBD-related surgery, n (%)† 34 (29.8)
Previous exposure to anti-TNFα therapy, n (%)
0 10 (8.8)
1 40 (35.1)
2 59 (51.7)
3 5 (4.4)
Anti-TNFα refractory disease, n (%) 88 (84.6)
Primary non-responders 36 (40.9)
Secondary loss of response 52 (59.1)
Concomitant steroid therapy, n (%)
Prednisolone 42 (36.8)
Budesonide 32 (28.1)
Concomitant IBD medication, n (%)
Immunomodulator 27 (23.7)
Thiopurines‡ 20 (17.5)
Tacrolimus 7 (6.1)
5-ASA 14 (12.3)
†Five patients with ileostomy, ileoanal pouch anastomosis, or ileorectal
anastomosis (the remainder received; 26 ileocolonic, 2 small intestine,
and 1 colonic resections).
‡Azahiorpine/mercaptopurine/thioguanine.
B, behavior; CD, Crohn’s disease; E, extent; IBD-U, inflammatory bowel
disease unclassified; L, location; N, numbers; TNFα, tumor necrosis fac-
tor alpha; UC, ulcerative colitis; 5-ASA, 5-aminosalicylic acid.
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The mean SES-CD decreased from 12 (SD 5.1) at baseline to
7.7 points (SD 5.9) at week 16 (P < 0.001). The Rutgeerts’ score
decreased from 3.2 (SD 0.7) at baseline to 2.5 points (SD 1.3) at
week 16 (P = 0.003). Mayo endoscopic score decreased from 2.3
(SD 0.7) at baseline to 1.5 points (SD 1.1) at week 16
(P < 0.001) (Fig. S2). Sixty patients with an endoscopic response
Table 2 Univariable and multivariable logistic regression analysis of factors associated with vedolizumab endoscopic response at week 16
Univariable analysis Multivariable analysis
Baseline characteristics Response, yes
n = 60 (%)
Response, no
n = 54 (%)
P-value OR [95% CI] P-value
Sex
Male 20 (33) 24 (44) 0.25 — —
Smoking
Yes 14 (23) 8 (15) 0.23 — —
IBD type
CD 32 (53) 36 (67) 0.18 — —
UC 28 (47) 18 (33) 0.52 [0.24–1.15] 0.11
Prior surgery for CD 17 (28) 17 (32) 0.84 — —
Steroid induction 35 (58) 40 (74) 0.11 1.87 [0.83–4.23] 0.13
Anti-TNFα refractory 48 (81) 45 (83) 0.81 — —
Endoscopic disease severity at baseline
Mild 8 (13) 8 (15) 0.12† — —
Moderate 36 (60) 24 (44) — —
Severe 16 (27) 22 (41) 1.99 [0.87–4.55] 0.10†
Disease location CD
Ileal 3 (9) 3 (8) 0.55‡ — —
Colonic 5 (16) 8 (22) — —
Ileocolonic 24 (75) 25 (69) — —
Upper GI 4 (6) 2 (4) — —
Disease location UC
Proctitis 0 (0) 0 (0) 0.36 — —
Left-sided 12 (43) 5 (28) — —
Pancolitis 16 (57) 13 (72) — —
Perianal disease
Yes 6 (10) 13 (24) 0.18 — —
†Severe endoscopic disease activity versus no severe endoscopic disease activity.
‡Colonic versus ileal and ileocolonic disease.
Univariable and multivariable analysis showed no significant associations between clinical baseline parameters and endoscopic response. CD, Crohn’s
disease; CI, confidence interval; GI, gastrointestinal disease activity; IBD, inflammatory bowel disease; N, numbers; OR, odds ratio; TNFα, tumor ne-
crosis factor alpha; UC, ulcerative colitis.
Table 3 Correlation coefficients between fecal calprotectin (μg/g) and endoscopy after induction (at week 16) and sustained endoscopic response (at
week 52)
Week 16 Week 52
FC FC† % decrease FC‡ FC FC§ % decrease FC¶
Endoscopic response 0.62** 0.40** 0.52** 0.67** 0.69** 0.61**
Endoscopic remission 0.47** 0.25* 0.41** 0.63** 0.52* 0.45*
Endoscopic inflammation 0.60** 0.36* 0.53** 0.71** 0.59* 0.52*
*P < 0.05.
**P < 0.001.
†FC indicates the absolute change between baseline and week 16.
‡% decrease indicates the relative change between baseline and week 16.
§FC indicates the absolute change between week 16 and week 52.
¶% decrease indicates the relative change between week 16 and week 52.
Spearman’s correlation between fecal calprotectin and endoscopic response, endoscopic remission, and endoscopic inflammation (no/mild/moderate/
severe) at week 16 and week 52. FC at week 16, n = 97/114 (both time points, n = 76) is correlated to endoscopy at week 16. FC at week 52, n = 35/60
(both time points, n = 30) is correlated with endoscopy at week 52. FC, fecal calprotectin (μg/g).
An objective clinical algorithm in vedolizumab-treated IBD patients RWM Pauwels et al.
4 Journal of Gastroenterology and Hepatology •• (2020) ••–••
© 2020 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
at week 16 continued VDZ; a total of 48/60 (80%) patients
underwent an endoscopy at week 52 (Fig. 1). A sustained endo-
scopic response at week 52 was observed in 35/48 (73%) patients
(14/23 UC and 21/25 CD patients, P = 0.07), of whom endoscopic
remission was observed in 22/48 (46%) patients (9/23 UC and
13/25 CD, P = 0.37). Mean SES-CD decreased to 3.0 points (SD
2.9) at week 52, Rutgeerts’ score decreased to 1.5 points (SD
1.2), and the Mayo endoscopic score decreased to 1.2 points (SD
1.2). eLOR at week 52 was observed in 13/48 (27%) patients
(Fig. S2) (UC 9/23 [39%] and CD 4/24 [17%], P = 0.111). A total
of 10/48 patients needed VDZ dose escalation, to every 6 weeks in
five patients and to every 4 weeks in five patients. After a median
follow-up time of 24 weeks (20 – 33), 1/10 (10%) patient
recaptured clinical response to VDZ and continued treatment.
Clinical predictors of endoscopic response at
week 16. Univariable and multivariable analysis showed no
significant associations between clinical parameters and endo-
scopic response at week 16 (Table 2). As depicted in the multivar-
iable analysis, there was no additional effect on the endoscopic
response for the use of corticosteroids at baseline (prednisolone
and budesonide), when corrected for endoscopic severity and
IBD type.
Fecal calprotectin. FC at baseline and week 16 were avail-
able in 76/114 (67%) patients. FC at week 52 was available in
35/60 (58%) patients. In 90/114 (79%) patients, FC was analyzed
using the ELISA, and 15/114 (13%) patients used the FC home
test at all time points. Only 9/114 (8%) patients intended to use
the FC home test but switched to the ELISA. The overall median
FC decreased significantly from 843.0 μg/g (403.0 – 1800.0) at
baseline to 256.5 μg/g (116.0 – 897.0) at week 16 (P < 0.001).
No statistical differences were observed between UC and CD.
Correlation between fecal calprotectin and endos-
copy. Median FC decreased significantly only in patients with
an endoscopic response at week 16 from 819.0 μg/g (243.0 –
1800.0) at baseline to 154.0 μg/g (49.0 – 254.5) at week 16
(P < 0.001). In patients without an endoscopic response at week
16, median FC was 974.50 μg/g (543.00 – 1748.50) at baseline
and 833 μg/g at week 16 (P = 0.60).
Within the group of patients with an endoscopic response at
week 16, a statistically non-significant increase in median FC
was observed from 154.0 μg/g (49.0 – 254.5) at week 16 to
224.0 μg/g (45.0 – 786.0) at week 52 (P = 0.41). No statistical dif-
ferences were observed between UC and CD.
Baseline FC was not correlated to endoscopic response, endo-
scopic remission, nor endoscopic inflammation at week 16
(r = 0.08, r = 0.18, and r = 0.16).
FC at week 16, as well as FC (FC at baseline  FC at week 16)
and percentage decrease in FC from baseline to week 16, corre-
lated significantly with endoscopic response, endoscopic remis-
sion, and endoscopic inflammation (no/mild/moderate/severe) at
week 16. Correlation coefficients (r) are mentioned in Table 3.
No statistical differences were observed between UC and CD, ex-
cept for the correlation between FC and endoscopic remission,
which reached only statistical significance for UC patients
(r = 0.407, P = 0.021) as compared with CD (r = 0.095,
P = 0.538).
Week 16 FC was not correlated with a sustained endoscopic
response/eLOR at week 52 (r =0.291, P = 0.076); no differences
were observed between UC (r = 0.30, P = 0.226) and CD pa-
tients (r = 0.24, P = 0.311).
FC at week 52, FC (FC at week 16  FC at week 52), and per-
centage decrease in FC from week 16 to week 52 correlated
Figure 2 Association between fecal calprotectin (μg/g) and endoscopic
response to vedolizumab at weeks 16 and 52. Receiver operating char-
acteristic curves for the optimal fecal calprotectin cut-off value to predict
endoscopic response after vedolizumab induction at week 16 and week
52. The area under the curve for endoscopic response at week
16 = 0.860, for endoscopic remission at week 16 = 0828, and for
sustained endoscopic response at week 52 = 0.942. Upper panel: ,
endoscopic response; , endoscopic remission. Lower panel: ,
sustained endoscopic response.
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significantly with sustained endoscopic response/eLOR endo-
scopic remission and endoscopic inflammation (no/mild/moder-
ate/severe) at week 52. The correlation coefficients (r) are
mentioned in Table 3.
Fecal calprotectin’s optimal cut-off value
predicting endoscopic response. At week 16,
FC < 200 μg/g predicted endoscopic response after induction
(AUC = 0.860, PPV = 94%, NPV = 67%, sensitivity = 64%, spec-
ificity = 94%, Fig. 2). FC > 450 μg/g at week 16 predicted an en-
doscopic non-response after induction (AUC = 0.858,
NPV = 83%, PPV = 87%, sensitivity = 87%, specificity = 83%,
Fig. 2). The specific diagnostic accuracies for UC and CD are
mentioned in Table 4.
No optimal cut-off value could be determined for the prediction
of endoscopic remission at week 16.
At week 52, FC < 200 μg/g predicted sustained endoscopic re-
sponse after 1 year (AUC = 0.942, PPV = 100%, NPV = 50% sen-
sitivity = 65%, specificity = 100%, Fig. 2). At week 52,
FC > 450 μg/g predicted eLOR (AUC = 0.942, NPV = 62%,
PPV = 96%, sensitivity = 81%, specificity = 89%). The cut-off
value for FC (FC at week 16  FC at week 52) of > 400 μg/g
is most strongly correlated with an eLOR (AUC = 0.969,
NPV = 96%, PPV = 86%, sensitivity = 86%, specificity = 96%).
Discussion
In this prospective cohort with a high percentage of anti-TNF-
exposed IBD patients, an objective endoscopic response at week
16 to VDZ is observed in approximately half of patients. Median
FC levels decreased significantly after the start of VDZ in patients
with an endoscopic response. FC levels and endoscopic response
at week 16 were significantly correlated: FC level of < 200 μg/g
at week 16 predicts endoscopic response with a diagnostic accu-
racy of 85% (PPV = 93%, NPV = 66%), and FC > 450 μg/g at
week 16 predicts endoscopic non-response with a diagnostic accu-
racy of 85% (PPV = 86%, NPV = 83%). Approximately 75% of
patients with an endoscopic response at week 16 had a sustained
endoscopic response at week 52. FC level of < 200 μg/g predicts
a sustained endoscopic response at week 52 with a diagnostic ac-
curacy of 94% (PPV = 50%, NPV = 100%), and FC level increase
of > 400 μg/g predicts eLOR with high diagnostic accuracy of
97% (PPV = 96%, NPV = 86%).
In this study, we propose an FC algorithm after VDZ induction to
predict endoscopic response as depicted in Figure 3. In this cohort,
an accurate correlation between FC levels and endoscopic disease
activity was shown for both UC and CD. FC levels of < 200 μg/g
at week 16 are indicative of endoscopic response; VDZ can be con-
tinued after induction without the need for routine endoscopic con-
firmation of the response and thus save unnecessary burden to
patients and costs. When FC levels are between 200 and 450 μg/g
after induction, we suggest to first explore the presence of possible
confounders (e.g. infections and NSAIDs). An endoscopy after in-
duction is required to evaluate the objective response. When FC
levels are> 450 μg/g after induction, an endoscopic response is un-
likely, and decisions have to be made on individual patient’s level.
In addition, FC level of< 200 μg/g at week 52 indicates a sustained
endoscopic response, in both UC and CD. An increase in FC level
of > 400 μg/g at week 52 (as compared with FC levels at week
16) indicates loss of endoscopic response, and in these cases, deci-
sions have to be made on individual patient’s level.
Decisions on the individual patient level in the absence of an en-
doscopic response at week 16 or loss of endoscopic response at
week 52 may include empiric or trough level-guided dose optimi-
zation. In these situations, endoscopic evaluation may be post-
poned. Recent data support early trough levels to predict
mucosal healing and response to VDZ.16–19 Other biomarkers such
as undetectable soluble mucosal addressin cell adhesion molecule
1 are potential predictors.20 An advanced algorithm integrating
therapeutic drug monitoring and FC levels may further improve
(early) optimization strategies during VDZ induction and mainte-
nance treatment.
In previous studies, analyzing data from the GEMINI UC regis-
tration trial on the ability of FC in combination with clinical data
on week 6 to predict endoscopic remission have shown only mod-
erate predictive value.21,22 A possible explanation for the discrep-
ancy between these findings and the accurate correlation of FC and
endoscopy in our study may be that in the VDZ registration trials
the evaluation of the response to VDZ induction have been sched-
uled too early.
The observed endoscopic remission rate of 20% in both UC and
CD at week 16 in our cohort is slightly lower as compared with
other real-world studies.11,23–25 For instance, the US VICTORY
consortium showed endoscopic remission, defined as the absence
Table 4 . Diagnostic accuracy for fecal calprotectin (μg/g) to predict endoscopic response after vedolizumab induction at week 16, specified for ulcer-
ative colitis and Crohn’s disease
FC < 200 μg/g
UC
Week 16
FC < 200 μg/g
CD
Week 16
FC > 450 μg/g
UC
Week 16
FC > 450 μg/g
CD
Week 16
AUC 0.874 0.877 0.874 0.872
Sensitivity (%) 61.9 66.7 81.0 91.7
Specificity (%) 100.0 91.7 100.0 75.0
PPV (%) 100.0 88.0 100.0 78.6
NPV (%) 57.9 73.3 73.3 90.0
Receiver operating characteristics for the optimal fecal calprotectin (FC) cut-off value to predict endoscopic response at week 16, n = 32 UC / 48 CD.
AUC, area under the curve; CD, Crohn’s disease; NPV, negative predictive value; PPV, positive predictive value; UC, ulcerative colitis.
An objective clinical algorithm in vedolizumab-treated IBD patients RWM Pauwels et al.
6 Journal of Gastroenterology and Hepatology •• (2020) ••–••
© 2020 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
of ulcers and/or erosions, in 35% in UC and 20% of CD patients at
6 months.26 In addition, a recent prospective cohort study showed
endoscopic remission (defined as SES-CD of ≤ 3) in 33% of CD
patients at week 26.12 In our study, definition for endoscopic re-
mission was more strict as compared with the aforementioned
studies that explains the lower endoscopic remission rates, as a
definition of a endoscopic Mayo 0/1 and SES-CD of ≤ 3 in our co-
hort would result in clearly higher remission rates, that is, 59% in
UC and 25% in CD. An additional explanation for the differences
in endoscopic remission is the timing of endoscopy in our study
(week 16 vs week 26). A delayed response to VDZ has been sug-
gested previously.27,28 However, additional objective data on this
issue are eagerly awaited. Week 52 sustained endoscopic response
was not comparable with the formerly described real-world stud-
ies, because in our study sustained response was objectified. In ad-
dition, eLOR is not previously described,29 and clinical data on
Figure 3 Fecal calprotectin (μg/g) algorithm to evaluate response to vedolizumab. VDZ, vedolizumab; FC, fecal calprotectin; TDM, therapeutic drug
monitoring. *FC increase of > 400 μg/g from week 16 to week 52 is most strongly correlated with an endoscopic loss of response. Preferably use
FC increase of > 400 μg/g from week 16 for objective response evaluation.
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loss of response to VDZ showed loss of response in 54% of UC
and 48% of CD patients per 100 person-years of follow-up.30
Major strengths of our study are the prospective inclusion of a
real-world cohort of anti-TNF-exposed patients with standardized
evaluation of FC levels and endoscopy at baseline, week 16 after
induction, and after 1 year of therapy. Objective response evalua-
tion after VDZ induction phase is highly relevant for therapeutic
decisions in daily clinical practice, for example, continuation of
drug therapy and optimization strategies. Furthermore, based on
objective response evaluation, our study may provide insight in
the timing of endoscopy, and the provided practical algorithm
may aid in individual clinical decision making and avoid routine
endoscopy procedures.
Nevertheless, some limitations of our study need to be consid-
ered, mostly attributed to the real-world design of this study in a
tertiary referral center. Firstly, FC levels can be influenced by sev-
eral factors such as stool composition, NSAIDs, blood admixture,
storage temperature, bowel movements, and infections. These fac-
tors were not mentioned in our inclusion and exclusion criteria and
could therefore affect the outcomes. Secondly, the endoscopists
were not blinded, nor were the endoscopies read centrally. How-
ever, the inter-observer variability is considered low because all
endoscopic results (images and video material if available) were
scored by one researcher. Finally, as only patients with a con-
firmed endoscopic response at week 16 continued with VDZ as
maintenance therapy, the week 52 analyses concern a selection
of the baseline population, and the sample size at week 52 was rel-
atively small. In addition, patients who stopped VDZ before week
16 were not analyzed in this study (per protocol analysis). For this,
we performed a sensitivity analysis, and no differences in out-
comes were observed (data not shown).
In conclusion, this prospective study demonstrates that as high
as half of IBD patients reach endoscopic response with VDZ ther-
apy at week 16, and approximately 75% of this patients had a
sustained endoscopic response after 1 year of therapy. A signifi-
cant correlation with FC levels and endoscopic response and loss
of response was demonstrated. FC levels of < 200 μg/g can be
used to prognosticate endoscopic response after induction and
long-term sustained response after 1 year of therapy. FC levels
of > 450 μg/g can be used to prognosticate endoscopic
non-response after induction, and an increase in FC level of
> 400 μg/g after induction indicates eLOR. This simple FC algo-
rithm may guide clinical decisions on the continuation of VDZ in
IBD patients.
Conference presentations. Poster presentation at the 12th
congress of ECCO—Inflammatory Bowel Diseases 2017.
(February 15–18, Barcelona, Spain). “P447 Vedolizumab induces
significantly higher endoscopic remission rates at week 16 in ul-
cerative colitis as compared to Crohn’s disease.”
Oral presentation at the Dutch Digestive Days (Veldhoven)
2017 “Vedolizumab induces significantly higher endoscopic re-
mission rates at week 16 in ulcerative colitis as compared to
Crohn’s disease.”
Poster presentation at the 13th congress of ECCO—Inflamma-
tory Bowel Diseases 2018 (February 14–17, Vienna, Austria),
“P433 Fecal calprotectin is correlated to endoscopic disease activ-
ity at Week 16 in IBD patients on vedolizumab therapy.”
References
1 Lobaton T, Vermeire S, Van Assche G, Rutgeerts P. Review article:
anti-adhesion therapies for inflammatory bowel disease. Aliment.
Pharmacol. Ther. 2014; 39: 579–94.
2 Engel T, Ungar B, Yung DE, Ben-Horin S, Eliakim R, Kopylov U.
Vedolizumab in IBD—lessons from real-world experience; a
systematic review and pooled analysis. J. Crohns Colitis 2018; 12:
245–57.
3 De Vos M, Dhooghe B, Vermeire S et al. Efficacy of vedolizumab for
induction of clinical response and remission in patients with moderate
to severe inflammatory bowel disease who failed at least two TNF
antagonists. United Eur. Gastroenterol J. 2018; 6: 439–45.
4 Shah SC, Colombel JF, Sands BE, Narula N. Mucosal healing is
associated with improved long-term outcomes of patients with
ulcerative colitis: a systematic review and meta-analysis. Clin.
Gastroenterol. Hepatol. 2016; 14: 1245–55.e8.
5 Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with
meta-analysis: mucosal healing is associated with improved long-term
outcomes in Crohn’s disease. Aliment. Pharmacol. Ther. 2016; 43:
317–33.
6 Neurath MF, Travis SP. Mucosal healing in inflammatory bowel
diseases: a systematic review. Gut 2012; 61: 1619–35.
7 Romkens TE, Gijsbers K, Kievit W, Hoentjen F, Drenth JP. Treatment
targets in inflammatory bowel disease: current status in daily practice.
J. Gastrointestin. Liver Dis. 2016; 25: 465–71.
8 Chudy-Onwugaje KO, Christian KE, Farraye FA, Cross RK. A state-
of-the-art review of new and emerging therapies for the treatment of
IBD. Inflamm. Bowel Dis. 2019; 25: 820–30.
9 Feagan BG, Rutgeerts P, Sands BE et al. Vedolizumab as induction
and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 2013;
369: 699–710.
10 Sandborn WJ, Feagan BG, Rutgeerts P et al. Vedolizumab as induction
and maintenance therapy for Crohn’s disease. N. Engl. J. Med. 2013;
369: 711–21.
11 Schreiber S, Dignass A, Peyrin-Biroulet L et al. Systematic review
with meta-analysis: real-world effectiveness and safety of vedolizumab
in patients with inflammatory bowel disease. J. Gastroenterol. 2018;
53: 1048–64.
12 Lowenberg M, Vermeire S, Mostafavi N et al. Vedolizumab induces
endoscopic and histologic remission in patients with Crohn’s disease.
Gastroenterology 2019.
13 Danese S, Sandborn WJ, Colombel JF et al. Endoscopic, radiologic,
and histologic healing with vedolizumab in patients with active
Crohn’s disease. Gastroenterology 2019.
14 Tursi A, Mocci G, Faggiani R et al. Vedolizumab is effective and safe
in real-life treatment of inflammatory bowel diseases outpatients: a
multicenter, observational study in primary inflammatory bowel
disease centers. Eur. J. Intern. Med. 2019; 66: 85–91.
15 de Jong MJ, Roosen D, Degens J et al. Development and validation of
a patient-reported score to screen for mucosal inflammation in
inflammatory bowel disease. J. Crohns Colitis 2019; 13: 555–63.
16 Dreesen E, Verstockt B, Bian S et al. Evidence to support
monitoring of vedolizumab trough concentrations in patients with
inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 2018; 16:
1937–46.e8.
17 Pouillon L, Vermeire S, Bossuyt P. Vedolizumab trough level
monitoring in inflammatory bowel disease: a state-of-the-art overview.
BMC Med. 2019; 17: 89.
18 Yacoub W, Williet N, Pouillon L et al. Early vedolizumab trough
levels predict mucosal healing in inflammatory bowel disease: a
multicentre prospective observational study. Aliment. Pharmacol. Ther.
2018; 47: 906–12.
19 Williet N, Boschetti G, Fovet M et al. Association between low trough
levels of vedolizumab during induction therapy for inflammatory
An objective clinical algorithm in vedolizumab-treated IBD patients RWM Pauwels et al.
8 Journal of Gastroenterology and Hepatology •• (2020) ••–••
© 2020 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
bowel diseases and need for additional doses within 6 months. Clin.
Gastroenterol. Hepatol. 2017; 15: 1750–7.
20 Paul S, Williet N, Di Bernado T et al. Soluble mucosal addressin cell
adhesion molecule 1 and retinoic acid are potential tools for therapeutic
drug monitoring in patients with inflammatory bowel disease treated
with vedolizumab: a proof of concept study. J. Crohns Colitis 2018;
12: 1089–96.
21 Reinisch W, Bressler B, Curtis R et al. Fecal calprotectin responses
following induction therapy with vedolizumab in moderate to severe
ulcerative colitis: a post hoc analysis of GEMINI 1. Inflamm. Bowel
Dis. 2019; 25: 803–10.
22 Waljee AK, Liu B, Sauder K et al. Predicting corticosteroid-free
endoscopic remission with vedolizumab in ulcerative colitis. Aliment.
Pharmacol. Ther. 2018; 47: 763–72.
23 Amiot A, Serrero M, Peyrin-Biroulet L et al. One-year effectiveness
and safety of vedolizumab therapy for inflammatory bowel disease: a
prospective multicentre cohort study. Aliment. Pharmacol. Ther. 2017;
46: 310–21.
24 Vivio EE, Kanuri N, Gilbertsen JJ et al. Vedolizumab effectiveness and
safety over the first year of use in an IBD clinical practice. J. Crohns
Colitis 2016; 10: 402–9.
25 Ylisaukko-Oja T, Aaltonen J, Nuutinen H et al. High treatment
persistence rate and significant endoscopic healing among real-life
patients treated with vedolizumab—a Finnish Nationwide
Inflammatory Bowel Disease Cohort Study (FINVEDO). Scand. J.
Gastroenterol. 2018; 53: 158–67.
26 Dulai PS, Singh S, Jiang X et al. The real-world effectiveness and
safety of vedolizumab for moderate-severe Crohn’s disease: results
from the US VICTORY consortium. Am. J. Gastroenterol. 2016; 111:
1147–55.
27 Kopylov U, Verstockt B, Biedermann L et al. Effectiveness and safety
of vedolizumab in anti-TNF-naive patients with inflammatory bowel
disease—a multicenter retrospective European study. Inflamm. Bowel
Dis. 2018; 24: 2442–51.
28 Plevris N, Chuah CS, Allen RM et al. Real-world effectiveness and
safety of vedolizumab for the treatment of inflammatory bowel disease:
the Scottish vedolizumab cohort. J. Crohns Colitis 2019; 13: 1111–20.
29 Pauwels RWM, de Vries AC, van der Woude CJ. Comment on
“Predictors and management of loss of response to vedolizumab in
inflammatory bowel disease”. Inflamm. Bowel Dis. 2018; 25: e59-e.
30 Peyrin-Biroulet L, Danese S, Argollo M et al. Loss of response to
vedolizumab and ability of dose intensification to restore response in
patients with Crohn’s disease or ulcerative colitis: a systematic review
and meta-analysis. Clin. Gastroenterol. Hepatol. 2019; 17: 838–46 e2.
Supporting information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
Figure S1. Endoscopic response and remission rates at week 16
and week 52.
Figure S2. Endoscopic scores at week 0, week 16 and week 52.
Table S1. Schematic overview of categorization of endoscopic
scores
RWM Pauwels et al. An objective clinical algorithm in vedolizumab-treated IBD patients
9Journal of Gastroenterology and Hepatology •• (2020) ••–••
© 2020 The Authors. Journal of Gastroenterology and Hepatology published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd
